Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CX-908
- Development stage
- Preclinical
- Lead developer
- CytomX
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
**CX-908** is a dually masked PROBODY® T-cell engager (TCE) developed by CytomX Therapeutics targeting **CDH3** (Cadherin-3, also known as P-cadherin) on tumor cells and **CD3** on T cells. It leverages CytomX's conditionally activated PROBODY platform, which masks the molecule in circulation and activates it selectively in the tumor microenvironment to improve tolerability and reduce systemic toxicity like cytokine release syndrome. Preclinical data demonstrate potent tumor regressions in breast and lung cancer xenograft models with a 100-fold tolerability improvement over unmasked CDH3xCD3 TCEs, including significantly reduced cytokine release.[2][5][7]
02
Targets
CD3 (T-cell surface glycoprotein CD3)CDH3 (Cadherin-3)
Beyond the preview
Go deeper on CX-908.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CX-908.